NeoStem, Inc. (AMEX: NBS)

NeoStem, Inc., founded in 1980 and headquartered in New York City, is an international biopharmaceutical company with operations in the U.S. and China focused on the development of proprietary cellular therapies in oncology, immunology and regenerative medicine. The company provides stem cell collection, processing and storage services in the U.S. through its network of adult stem cell and newborn cord blood cell collection centers, primarily in the Southern California and Northeast markets. Through Progenitor Cell Therapy, LLC, its wholly-owned subsidiary acquired in January 2011, the company is engaged in a wide range of services in the cell therapy market. The company effectively holds 80% interest in Athelos, Inc., a subsidiary of Progenitor Cell Therapy, which in March 2011 acquired rights and technology for a T-cell based immunomodulatory therapeutic expected to enter Phase 1 studies in autoimmune disorders in 2012 with their partner Becton, Dickinson and Company (NYSE: BDX). The company further strengthened its breadth in cellular therapies through its recent October 2011 acquisition of Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease with lead product candidate entering a Phase 2 study for acute myocardial infarction. Leveraging China’s regulatory and scientific stem cell therapy environment, the company launched several initiatives, such as establishing an R&D laboratory and processing facility in Beijing to provide comprehensive adult stem cell collection, processing and storage capabilities in support of its therapeutic programs and forming collaborations for its licensed stem cell applications in orthopedics, anti-aging, cosmetics and wellness treatments, including medical tourism opportunities. Finally, the company has controlling 51% ownership interest in Suzhou Erye Pharmaceuticals Company Ltd, a vertically-integrated developer, manufacturer and distributor of generic antibiotic products, which it is planning to divest to focus on stem cell activities. NeoStem is the winner of The New Economy’s 2010 Biotech Award for “Best Stem Cell Company”.

INCOME STATEMENT HIGHLIGHTS

- REVENUE: $17.8 million
- GROSS PROFIT: $3.9 million
- NET INCOME: ($7.5 million)
- DILUTED EPS: ($0.08)

All figures for three months ended September 30, 2011

BALANCE SHEET HIGHLIGHTS

- CASH: $11.7 million
- WORKING CAPITAL: $13.6 million
- TOTAL ASSETS: $168.2 million
- NET WORTH: $100.4 million

All figures as of September 30, 2011

RECENT COMPANY HEADLINES

November 11, 2011 — Neostem Inc. announced it has reported its unaudited results for the three and nine months ended September 30, 2011. Revenues for the three and nine months ended September 30, 2011 were $17.8 million and $55.9 million compared to $16.5 million and $51.7 million for the same periods in 2010.

October 17, 2011 — Neostem Inc. announced it has completed the acquisition of Amorcyte, Inc., taking ownership of a strong patent portfolio covering the use of hematopoietic stem cells for treatment of cardiac ischemia. Amorcyte is currently recruiting trial sites in connection with the launch of Phase 2 clinical trial for its lead product for the treatment of acute myocardial infarction, AMR-001, which is expected to begin patient enrollment by the end of the first quarter of 2012.